Entering text into the input field will update the search result below

Societal CDMO, Lannett amend license and supply deal

Jul. 12, 2022 7:25 AM ETSocietal CDMO, Inc. (SCTL)By: Preeti Singh, SA News Editor
  • Societal CDMO (NASDAQ:SCTL) has announced an amendment to its license and supply deal with Lannett Company for the marketing of Verapamil PM and Verelan SR products.
  • The amendment awards Societal (SCTL) potential new GMP manufacturing agreements targeting injectable products for multiple additional Lannett development projects.
  • The CDMO will also receive improved overall economics, including a 10% growth in the profit share component of revenue from Verapamil PM product sales, as well as immediate and scheduled increases in manufacturing prices.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About SCTL

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Societal CDMO, Inc.
Daré Bioscience, Inc.
Medicine Man Technologies, Inc.
Sol-Gel Technologies Ltd.
Cognition Therapeutics, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.